ATE551069T1 - Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung - Google Patents

Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung

Info

Publication number
ATE551069T1
ATE551069T1 AT03725536T AT03725536T ATE551069T1 AT E551069 T1 ATE551069 T1 AT E551069T1 AT 03725536 T AT03725536 T AT 03725536T AT 03725536 T AT03725536 T AT 03725536T AT E551069 T1 ATE551069 T1 AT E551069T1
Authority
AT
Austria
Prior art keywords
compositions
fusion polypeptide
polypeptide vaccines
mucin fusion
mucin
Prior art date
Application number
AT03725536T
Other languages
English (en)
Inventor
Jan Holgersson
Original Assignee
Recopharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recopharma Ab filed Critical Recopharma Ab
Application granted granted Critical
Publication of ATE551069T1 publication Critical patent/ATE551069T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT03725536T 2002-04-22 2003-04-22 Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung ATE551069T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37509502P 2002-04-22 2002-04-22
PCT/IB2003/002207 WO2003088995A2 (en) 2002-04-22 2003-04-22 Mucin fusion polypeptide vaccines, compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE551069T1 true ATE551069T1 (de) 2012-04-15

Family

ID=29251230

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03725536T ATE551069T1 (de) 2002-04-22 2003-04-22 Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung

Country Status (8)

Country Link
US (2) US8034351B2 (de)
EP (1) EP1517700B1 (de)
JP (1) JP2005530493A (de)
AT (1) ATE551069T1 (de)
AU (1) AU2003228067B2 (de)
CA (1) CA2483473A1 (de)
ES (1) ES2385032T3 (de)
WO (1) WO2003088995A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1958642A1 (de) 2000-12-22 2008-08-20 Dana-Farber Cancer Institute Regulierung des Zellwachstums durch MUC1
AU2003233008B2 (en) * 2002-04-22 2008-04-24 Recopharma Ab Fusion polypeptides and methods for inhibiting microbial adhesion
WO2005042573A1 (en) * 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
JP4549666B2 (ja) * 2003-12-12 2010-09-22 タカラバイオ株式会社 抗体の製造方法
US7807636B1 (en) 2004-11-12 2010-10-05 Wisconsin Alumni Research Foundation Bovine P-selectin glycorpotein ligand-1
ATE527285T1 (de) 2005-01-28 2011-10-15 Univ Ramot Anti-muc1-alpha-beta-antikörper
FR2886298A1 (fr) * 2005-05-24 2006-12-01 Ifremer Anticorps ou fragment d'anticorps couple a un agent immunogene
JP2009544760A (ja) * 2006-01-23 2009-12-17 レコファーマ アーベー 酵母におけるオリゴマンノースまたはヒト様グリカンを担持するタンパク質の産生およびその使用
EP2264061A1 (de) * 2006-01-26 2010-12-22 Recopharma AB Zusammensetzung und verfahren zur Bekämpfung von viralen Infektionen
US7871784B2 (en) 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
WO2008118487A2 (en) 2007-03-26 2008-10-02 University Of Massachusetts Medical School Compositions and methods for incresing immunogenicity of glycoprotein vaccines
WO2009136298A2 (en) * 2008-05-09 2009-11-12 Recopharma Ab Compositions and methods for inhibiting shiga toxin and shiga-like toxin
AU2009251328B2 (en) * 2008-05-30 2014-10-02 Glycofi, Inc. Yeast strain for the production of proteins with terminal alpha-1,3-linked galactose
AU2011347237A1 (en) * 2010-12-21 2013-07-11 Recopharma Ab Tear substitutes
DK2859015T3 (en) 2012-06-08 2018-06-18 Alkermes Inc LIGANDS MODIFIED BY CIRCULAR MODIFICATION AS AGONISTS AND ANTAGONISTS
CN104800838B (zh) * 2015-04-14 2018-01-09 深圳市中联生物科技开发有限公司 MUC1‑Fc多肽疫苗及其制备方法和应用
JP6441167B2 (ja) * 2015-05-15 2018-12-19 愛三工業株式会社 蒸発燃料処理装置
KR102148866B1 (ko) * 2017-08-10 2020-10-14 주식회사 굳티셀 암 치료를 위한 t 세포의 활성화 방법
EP4314073A4 (de) 2021-03-24 2025-02-19 Alkermes, Inc. Upar-antikörper und fusionsproteine damit

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4710761A (en) 1985-07-09 1987-12-01 American Telephone And Telegraph Company, At&T Bell Laboratories Window border generation in a bitmapped graphics workstation
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
EP0406857B1 (de) * 1989-07-07 1995-05-24 Takeda Chemical Industries, Ltd. Proteine und deren Herstellung
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
PT671923E (pt) 1992-10-09 2001-10-30 Advanced Tissue Sciences Inc Celulas de reserva do figado
US5516964A (en) 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
US5879675A (en) * 1994-03-15 1999-03-09 Medical College Of Pennsylvania And Hahnemann University Compositions and methods for vaccines comprising α-galactosyl epitopes
AUPN568095A0 (en) 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
DE69840723D1 (de) * 1997-02-11 2009-05-20 Immunomedics Inc Stimulation einer immunantwort durch antikörper, welche mit dem alpha-galaktosylepitop markiert sind
SE9701127D0 (sv) 1997-03-26 1997-03-26 Karolinska Innovations Ab Antigenic fusionprotein carrying GALal, 3GAL epitopes

Also Published As

Publication number Publication date
JP2005530493A (ja) 2005-10-13
AU2003228067B2 (en) 2008-05-29
ES2385032T3 (es) 2012-07-17
AU2003228067A1 (en) 2003-11-03
US8034351B2 (en) 2011-10-11
EP1517700A2 (de) 2005-03-30
EP1517700B1 (de) 2012-03-28
US20120034220A1 (en) 2012-02-09
CA2483473A1 (en) 2003-10-30
US20040002585A1 (en) 2004-01-01
WO2003088995A3 (en) 2004-06-03
WO2003088995A2 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
FR20C1016I1 (de)
DK1584685T3 (da) Tumorassocieret antigenderivater fra Mage-familien, anvendt til fremstilling af fusionsproteiner med T-hjælper epitoper og sammensætninger til vaccination
CY1119106T1 (el) Αντισωματα εναντι masp-2
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
UA93855C2 (ru) Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
ATE405647T1 (de) Rekombinantes gelatin in impstoffen
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
EP1594536A4 (de) Adjuvante influenza-vakzine
ATE481108T1 (de) Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
IL210378A0 (en) Tumor associated antigen, peptides thereof, and use of same as ati-tumor vaccines
DK1373301T3 (da) Reducering af immunogeniciteten af fusionsproteiner
UA85536C2 (en) Viral antigens
WO2004022709A3 (en) Epitope sequences
NO20041157L (no) HIV-GAG kodonoptimaliserte DNA-vaksiner
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
DK1530637T3 (da) Carlsberg-subtilisin-proteiner med nedsat immunogenitet
DE60230456D1 (de) Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
WO2003088995A3 (en) Mucin fusion polypeptide vaccines, compositions and methods of use thereof
WO2005013904A3 (en) Sars nucleic acids, proteins, vaccines, and uses thereof
EP1565080A4 (de) Neue immunogene proteine von leptospira
WO2003093298A3 (en) Immunogenic peptides
DK1444356T3 (da) Identifikation af epitoper og mindskelse af allergeniciteten af fødevareproteiner
DK1578772T3 (da) Cytokiner og cytokinreceptorer med reduceret immunogenicitet